TY - JOUR
T1 - The phosphorescence oxygen analyzer as a screening tool for disorders with impaired lymphocyte bioenergetics
AU - Al-Jasmi, Fatma
AU - Penefsky, Harvey S.
AU - Souid, Abdul Kader
N1 - Funding Information:
We thank Aysha Al Mansouri and Farida Marzouqi for calibrating the instruments, Dr. Sami Shaban for developing the software, Mr. Thachillath Pramathan for processing volunteer samples, Dr. Gazala Balhaj for providing umbilical cord blood samples and Dr. Jozef Hertecant and Dr. Fatma Bastaki for providing some patient samples. The study is supported by the United Arab Emirates University .
PY - 2011/12
Y1 - 2011/12
N2 - This study aimed to show the feasibility of using the phosphorescence oxygen analyzer to screen for clinical disorders with impaired cellular bioenergetics. [O 2] was determined as function of time from the phosphorescence decay of Pd (II) meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin. In sealed vials, O 2 consumption by peripheral blood mononuclear cells was linear with time, confirming its zero-order kinetics. Cyanide inhibited O 2 consumption, confirming the oxidation occurred in the mitochondrial respiratory chain. The rate of respiration (mean±SD, in μM O 2 per min per 10 7 cells, set as the negative of the slope of [O 2] vs. t) for adults was 2.1±0.8 (n=18), for children 2.0±0.9 (n=20), and for newborns (umbilical cord samples) 0.8±0.4 (n=18), p<0.0001. For an 8-year-old patient with reduced NADH dehydrogenase and pyruvate dehydrogenase activities in the muscle, the rate was 0.7±0.2 (n=3) μM O 2 per min per 10 7 cells. For a 3-month-old patient with hepatocerebral mitochondrial DNA depletion syndrome (MDS) with confirmed mutations in the MPV17 gene, the rate was 0.6μM O 2 per min per 10 7 cells. For an18 month-old patient with MDS and confirmed mutations in the POLG gene, the rate was 0.5μM O 2 per min per 10 7 cells. For a 6-year-old patient with MDS and confirmed mutations in the POLG gene, the rate was 0.6μM O 2 per min per 10 7 cells. For 1-week-old patient with congenital lactic acidemia and hypotonia (confirmed mutations in DLD gene), the rate was 1.5μM O 2 per min per 10 7 cells. For three siblings (9-year-old male, 8-year-old male and 2-month-old female) with congenital progressive myopathy, the rates were 0.9, 0.6 and 1.2μM O 2 per min per 10 7 cells, respectively. Four patients with congenital lactic acidemia (with inadequate work-up) were also studied; their rates were 0.2, 1.5, 0.3 and 1.7μM O 2 per min per 10 7 cells. This novel approach permits non-invasive, preliminary assessment of cellular bioenergetics. Potential applications and limitations of this technique are discussed.
AB - This study aimed to show the feasibility of using the phosphorescence oxygen analyzer to screen for clinical disorders with impaired cellular bioenergetics. [O 2] was determined as function of time from the phosphorescence decay of Pd (II) meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin. In sealed vials, O 2 consumption by peripheral blood mononuclear cells was linear with time, confirming its zero-order kinetics. Cyanide inhibited O 2 consumption, confirming the oxidation occurred in the mitochondrial respiratory chain. The rate of respiration (mean±SD, in μM O 2 per min per 10 7 cells, set as the negative of the slope of [O 2] vs. t) for adults was 2.1±0.8 (n=18), for children 2.0±0.9 (n=20), and for newborns (umbilical cord samples) 0.8±0.4 (n=18), p<0.0001. For an 8-year-old patient with reduced NADH dehydrogenase and pyruvate dehydrogenase activities in the muscle, the rate was 0.7±0.2 (n=3) μM O 2 per min per 10 7 cells. For a 3-month-old patient with hepatocerebral mitochondrial DNA depletion syndrome (MDS) with confirmed mutations in the MPV17 gene, the rate was 0.6μM O 2 per min per 10 7 cells. For an18 month-old patient with MDS and confirmed mutations in the POLG gene, the rate was 0.5μM O 2 per min per 10 7 cells. For a 6-year-old patient with MDS and confirmed mutations in the POLG gene, the rate was 0.6μM O 2 per min per 10 7 cells. For 1-week-old patient with congenital lactic acidemia and hypotonia (confirmed mutations in DLD gene), the rate was 1.5μM O 2 per min per 10 7 cells. For three siblings (9-year-old male, 8-year-old male and 2-month-old female) with congenital progressive myopathy, the rates were 0.9, 0.6 and 1.2μM O 2 per min per 10 7 cells, respectively. Four patients with congenital lactic acidemia (with inadequate work-up) were also studied; their rates were 0.2, 1.5, 0.3 and 1.7μM O 2 per min per 10 7 cells. This novel approach permits non-invasive, preliminary assessment of cellular bioenergetics. Potential applications and limitations of this technique are discussed.
KW - Mitochondria
KW - Oxygen
KW - Respiration
KW - Respiratory chain
UR - http://www.scopus.com/inward/record.url?scp=82255179332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82255179332&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2011.09.023
DO - 10.1016/j.ymgme.2011.09.023
M3 - Article
C2 - 21996136
AN - SCOPUS:82255179332
SN - 1096-7192
VL - 104
SP - 529
EP - 536
JO - Molecular Genetics and Metabolism
JF - Molecular Genetics and Metabolism
IS - 4
ER -